Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 May;34(3):e14900.
doi: 10.1111/dth.14900. Epub 2021 Mar 2.

Botulinum toxin and platelet rich plasma as innovative therapeutic modalities for keloids

Yomna Mazid El-Hamd Neinaa  1 , Toka Ahmad Elsayed  2 , Dareen Ali Mohamed  3 , Nashwa Naeem Elfar  1
Affiliations
Randomized Controlled Trial

Botulinum toxin and platelet rich plasma as innovative therapeutic modalities for keloids

Yomna Mazid El-Hamd Neinaa et al. Dermatol Ther. 2021 May.

Abstract

Keloids characterize a definitely challenging type of cutaneous scars for which a diversity of therapeutic modalities has been suggested. The aim of this work was to compare the therapeutic efficacy of intralesional injection of botulinum toxin type-A (BTX-A), platelet rich plasma (PRP), and triamcinolone acetonide (TAC) in keloids. A total of 60 keloids patients were enrolled and divided randomly into three equal groups. Group I treated by intralesional BTX-A injection, group II treated by intralesional PRP injection, and group III treated by intralesional TAC injection. Clinical assessment was done by Vancouver Scar Scale (VSS), Verbal Rating Scale (VRS), and dermoscopic examination. Additionally, histopathology and immunohistochemistry of connective tissue growth factor (CTGF) expression were evaluated. The results of this study revealed significant improvement of both VSS and VRS in response to all treatment modalities. There was significant improvement of VSS in BTX-A and PRP groups more than TAC group. However, no significant difference observed between BTX-A and PRP groups. Immunohistochemical examination showed significant decrease of CTGF expression after treatment in BTX-A and PRP groups more than TAC group. In conclusion, both BTX-A and PRP could yield a chance for cosmetically better outcomes in keloids treatment than conventional TAC injection.

Keywords: botulinum toxin A; connective tissue growth factor; keloids; platelet rich plasma; triamcinolone acetonide.

PubMed Disclaimer

References

REFERENCES

    1. Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018;19(3):711.
    1. Mari W, Alsabri SG, Tabal N, Younes S, Sherif A, Simman R. Novel insights on understanding of keloid scar: article review. J Am Coll Clin Wound Spec. 2016;7(1-3):1-7.
    1. Limmer EE, Glass DA 2nd. A review of current keloid management: mainstay monotherapies and emerging approaches. Dermatol Ther. 2020;10(5):931-948.
    1. Hochman B, Locali RF, Matsuoka PK, Ferreira LM. Intralesional triamcinolone acetonide for keloid treatment: a systematic review. Aesthetic Plast Surg. 2008;32(4):705-709.
    1. Fathi A, Khorasani Q, Forghani S. Botulinum toxin type a effects on the treatment of keloid lesions: comparison of intralesional two different doses. Int J Med Res Prof. 2017;3:306-311.

Publication types

Substances

LinkOut - more resources